Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 3631 results
Biozone completes acquisition of Cocrystal Discovery and begins transformation to high growth biotech company
06 January 2014
Biozone Pharmaceuticals announced that it has finalized its planned merger with Cocrystal Discovery, a privately-held, biotechnology company developing antiviral therapeutics for human diseases. Cocrystal Discovery has previously received strategic investments from Teva Pharmaceuticals, Opko Health and The Frost Group.
Drug Research > Drug Discovery & Development > News
AstraZeneca buys Probiodrug's CDK9 inhibitor program
06 January 2014 | By PBR Staff Writer
Germany-based biopharmaceutical firm Probiodrug has transferred its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to AstraZeneca.
Drug Research > Drug Discovery & Development > News
TauRx Therapeutics adds 35 new clinical trial centers for Alzheimer's drug
06 January 2014 | By PBR Staff Writer
TauRx Therapeutics, a Singapore-based biopharmaceutical company, has announced the addition of 35 new clinical trial centers in the US for its Alzheimer's disease drug LMTX.
Drug Research > Drug Discovery & Development > News
Asterias Biotherapeutics leases facilities for expanded product development and manufacturing
03 January 2014
Asterias Biotherapeutics and BioTime announced that Asterias has executed a long term lease for a research, development and manufacturing facility to house all of its cell therapy product development activities.
Drug Research > Drug Discovery & Development > News
Threshold Pharmaceuticals announces target enrollment of 620 patients achieved in pivotal Phase III trial of TH-302 in advanced soft tissue sarcoma
31 December 2013
Threshold Pharmaceuticals announced that the target enrollment of 620 patients with advanced soft tissue sarcoma has been achieved in the company's pivotal Phase III trial of TH-302, its investigational hypoxia-targeted drug. The enrollment achievement triggers a milestone payment of $12.5m from Merck KGaA, Darmstadt, Germany. Threshold has a global license and co-development agreement with Merck for TH-302, which includes an option for Threshold to co-commercialize in the U.S.
Drug Research > Drug Discovery & Development > News
Veloxis Pharmaceuticals announces NDA submission for Envarsus in kidney transplant recipients
30 December 2013
Veloxis Pharmaceuticals announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for the marketing and sale of Envarsus (formerly LCP-Tacro) for the prevention of organ rejection in kidney transplant recipients.
Drug Research > Drug Discovery & Development > News
PeptiDream announces collaboration and license agreement with Lilly to discover macrocyclic peptide drug candidates
23 December 2013
PeptiDream, a Tokyo-based biopharmaceutical company, announced that they have entered into a Collaboration and License Agreement with US-based Eli Lilly and Company on 19 December 2013.
Drug Research > Drug Discovery & Development > News
Jazz Pharmaceuticals enters into definitive agreement to acquire Gentium
20 December 2013
Jazz Pharmaceuticals and Gentium have entered into a definitive agreement pursuant to which a subsidiary of Jazz Pharmaceuticals will make a cash tender offer of $57.00 per share for all outstanding Gentium ordinary shares and American Depositary Shares, in a transaction that is valued at approximately $1bn.
Drug Research > Drug Discovery & Development > News
Boehringer, Circuit Therapeutics to discover new treatment options for psychiatric disorders
19 December 2013 | By PBR Staff Writer
Boehringer Ingelheim has entered into a research collaboration agreement with and Circuit Therapeutics to discover new ways of treating psychiatric disorders.
Drug Research > Drug Discovery & Development > News
BioCryst advances oral plasma kallikrein inhibitors for hereditary angioedema into preclinical development
19 December 2013
US-based BioCryst Pharmaceuticals has selected two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily, oral treatments for the prevention of hereditary angioedema (HAE) attacks.
Drug Research > Drug Discovery & Development > News
Merck Serono, CNIO partner for new treatment options for cancer patients
19 December 2013 | By PBR Staff Writer
Merck Serono has signed a license agreement with the Spanish National Cancer Research Centre (CNIO) in Madrid in the area of cancer drug development and will build upon CNIO research discoveries to support the development and commercialization of new compounds in the field of oncology.
Drug Research > Drug Discovery & Development > News
AnaptysBio, Momenta Pharma enter antibody development deal
18 December 2013 | By PBR Staff Writer
US-based privately-held therapeutic antibody firm AnaptysBio has commenced an antibody development program with Momenta Pharmaceuticals, focused on the development of new antibodies against a therapeutically relevant target.
Drug Research > Drug Discovery & Development > News
Pfenex to support development of new rPA-based anthrax vaccine
18 December 2013 | By PBR Staff Writer
Pfenex has received a subcontract from Leidos Holdings (LDOS) to support the development of an anthrax vaccine containing its recombinant protective antigen (rPA) and a novel, immune-enhancing adjuvant.
Drug Research > Drug Discovery & Development > News
Stelis, Pieris partner for new Anticalin therapeutics in ophthalmology
17 December 2013 | By PBR Staff Writer
Stelis Biopharma and Pieris, a next generation therapeutic protein R&D firm, have started a long-term collaboration for clinical development and commercialization of multiple novel Anticalin-based protein therapeutics worldwide, primarily focusing on ophthalmology.
Drug Research > Drug Discovery & Development > News
BIND Therapeutics and Amgen amend collaboration agreement for kinase inhibitor nanomedicine
13 December 2013
BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has amended its development and commercialization collaboration agreement with Amgen to extend the period during which Amgen may exercise its option by six months.
Drug Research > Drug Discovery & Development > News
91-105 of 3631 results